BGC > Produktsuche > Umbralisib | 1532533-67-7

Description:
Umbralisib is an orally bioavailable and selective PI3K delta inhibitor that targets delta isoform with nanomolar potency, which is approximately 1000-fold selective over alpha isoform, >30-50 fold over beta isoform and >15-50 fold over gamma isoforms. Umbralisib is developed for lymphoma therapy.

• Molecular Weight:571.5
• Boiling Point:737.4±60.0 °C at 760 mmHg

Molecular Formula:
C31H24F3N5O3
Canonical SMILES:
CC(C)OC1=C(C=C(C=C1)C2=NN(C3=NC=NC(=C23)N)C(C)C4=C(C(=O)C5=C(O4)C=CC(=C5)F)C6=CC(=CC=C6)F)F
InChI:
InChI=1S/C31H24F3N5O3/c1-15(2)41-24-9-7-18(12-22(24)34)27-26-30(35)36-14-37-31(26)39(38-27)16(3)29-25(17-5-4-6-19(32)11-17)28(40)21-13-20(33)8-10-23(21)42-29/h4-16H,1-3H3,(H2,35,36,37)/t16-/m0/s1
InChIKey:
IUVCFHHAEHNCFT-INIZCTEOSA-N
Solubility:
Soluble in DMSO.
Appearance:
Solid Powder
Storage: Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -65℃ for long term (months to years).
Synonyms:
TGR-1202; TGR 1202; TGR1202; RP5264; 2-[(1S)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one